As mentioned, DDR inhibitors have the potential to convert “cold” tumors to “hot” tumors, enhancing the sensitivity to immune checkpoint blockade, by promoting the exposure of neoantigens on the cancer cell surface and by activating interferon signaling [194]. The gene discussed is DDR1; the disease is cancer.